Adsorption to container surfaces and to plastics

On the subject in the title: Adsorption to container surfaces and to plastics Working notes rather than a conclusion.

A documentation question rather than an analytical one.

I have a certificate in front of me that reports a purity figure, names a technique, gives a wavelength, and stops. No gradient, no column, no injection volume, no chromatogram.

What can I legitimately conclude from that document? My instinct is "almost nothing, but not literally nothing", and I would like to know where the people who read these professionally draw the line.

Excipients and their purposes: mannitol, sucrose, or other sugars in lyophilised formulations protect the peptide during drying and storage. They are not impurities; they are functional components.

post #2 is right about the mechanism and I think understates the practical bit.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

Worth separating two things that post #3 runs together.

Amino acid residues and formulation: the specific sequence and composition of a peptide affects what formulation conditions it tolerates. Sequences high in methionine need more antioxidant protection. Sequences prone to aggregation need different pH or additive protection.

Container closure: the vial material, rubber closure, and sealing all affect permeability to water and oxygen. Glass is less permeable than plastic. Rubber quality matters.

Emulsification and suspensions: some formulations are emulsions or suspensions rather than solutions. Semaglutide formulations are solutions; some other compounds are suspensions. The physical form affects stability and administration.

On post #4 — agreed on the reasoning, with one qualification.

Buffers and pH: the pH of a solution is buffered to maintain stability. The buffer system (phosphate, Tris, or other) is chosen to keep the solution at the pH where the peptide is most stable.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

I read post #8 twice before replying, because I had assumed the opposite.

Isotonicity: an isotonic solution has the same osmotic pressure as blood. Non-isotonic solutions can cause discomfort on injection. Injectable peptide solutions are formulated to be isotonic.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

Antioxidants: compounds that prevent oxidation (which damages peptides) are sometimes included. Methionine oxidation is a common degradation pathway and antioxidants help prevent it.

Preservatives: solutions for multi-dose vials contain preservatives (benzyl alcohol, phenol, or others) to inhibit microbial growth after the vial has been entered. Single-use vials do not need preservatives.

This follows post #11 rather than contradicting it.

Fill volume and headspace: the amount of solution in a vial and the air above it affect how much the solution is exposed to oxygen during storage. Less headspace means less oxygen exposure.